周三，Truist Securities调整了对Incyte Corporation (NASDAQ:INCY)的立场，将该股票从买入下调至持有，同时将目标价从83美元下调至74美元。这一决定是因为这家生物制药公司即将面临其旗舰产品Jakafi的专利到期。 在最近的一份声明中，Truist Securities承认Incyte成功推出了Opzelura并努力使其管线多样化。尽管如此，该公司表示担心 ...
Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in ...
Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...
生物制药公司Incyte Corporation (NASDAQ: INCY)在TD Cowen的评级中保持买入评级，目标价为80.00美元。 这一评估是在公司在欧洲肿瘤内科学会(ESMO)会议上展示更新数据之后做出的。 新数据来自其CDK2抑制剂'667的I期研究，该药物正在晚期实体瘤患者中进行测试。 更新的结果显示，随着更长的随访期和更高的剂量，'667导致的反应数量比早期结果增加。具体而言， ...
Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo(axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...
Zacks.com on MSN5 天
Incyte Announces Promising New Data on Oncology Candidate at ESMOIncyte INCY announced new data from a phase I study on pipeline candidate INCB123667 in patients with advanced solid ...
Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...
Incyte (INCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebovitz from ...
Incyte Corp (INCY) stock saw a modest uptick, ending the day at $66.82 which represents a slight increase of $1.65 or 2.53% from the prior close of $65.17. The stock opened at $66.22 and touched a low ...
A common immunotherapy approach helped stave off disease progression in patients with a form of anal cancer that is caused by ...
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, ...
JMP Securities analyst Reni Benjamin has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. Reni Benjamin has ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈